Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol "ALPS" in October 2025, Marking the Company's Transition to the U.S. Public Markets KUALA LUMPUR, Malaysia, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its financial results for the year ended March 31, 2026, and provides a business update. The Company has filed its annual report on Form 20-F, including its audited financial statements
